NZYM B Novozymes A/S Class B

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

        

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

February 2, 2024

Company announcement No. 07

On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously announced, the name of the combined company will be Novonesis.

Settlement of the Combination completed

The settlement of the Combination has now been successfully completed by the exchange of all shares of Chr. Hansen for 187,298,646 new Novozymes B-shares of nominally DKK 2 each (374,597,292 new Novozymes B-shares of nominally DKK 1) (the "Merger Consideration Shares") under the existing ISIN code DK0060336014 and the cash payment in lieu of fractional entitlements to Merger Consideration Shares via Euronext Securities Copenhagen has been initiated.

Eligible former shareholders of Chr. Hansen (the "Chr. Hansen Shareholders"), excluding Novo Holdings A/S ("Novo Holdings"), have received 1.5326 Merger Consideration Shares in exchange for each Chr. Hansen share that they held, and Novo Holdings has received 1.0227 Merger Consideration Shares in exchange for each Chr. Hansen share held with respect to Novo Holdings' holding of 28,983,112 Chr. Hansen shares and 1.5326 Merger Consideration Shares in exchange for each Chr. Hansen share held exceeding 28,983,112.

The Merger Consideration Shares issued have been admitted to trading and official listing on Nasdaq Copenhagen A/S on January 31, 2024, under the symbol "NZYM B" and the permanent ISIN code DK0060336014.

Chr. Hansen Shareholders restricted from receiving shares in the Combination

As further described in the exemption document, certain Chr. Hansen Shareholders with a registered address in, or who are resident or otherwise located in, or who are organized under the laws of certain jurisdictions, the ability to participate in the Combination and receive new B-shares has been restricted by the laws of such other jurisdictions (each a "Restricted Shareholder").

For such Restricted Shareholders only, the combined company will procure that the new B-shares that would otherwise be attributable to such Restricted Shareholders will be sold by Nordea Danmark, Filial af Nordea Bank Abp, Finland acting on behalf of the combined company, in a vendor placement (via Nasdaq Copenhagen or other trading venues in one or more tranches and outside the U.S. and other restricted jurisdictions) (the "Vendor Placement") and the cash proceeds from the Vendor Placement will be distributed in DKK to the Restricted Shareholders via a corporate action in Euronext as soon as practicably possible following completion of the Vendor Placement. Other shareholders in the combined company cannot participate in the Vendor Placement.

For further information on the Vendor Placement, reference is made to the exemption document available at .

Transaction website

For additional information, visit .

Contact information
Investor Relations  
Tobias Bjorklund
Anders Enevoldsen




Media Relations
  
Lina Danstrup



   

Attachment



EN
02/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Q1 update: Novonesis delivers 4% organic sales growth in line with exp...

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolution...

 PRESS RELEASE

Trading statement Q1 2024

Trading statement Q1 2024 Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales perfo...

 PRESS RELEASE

Resolutions from the annual shareholders’ meeting 2024

Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:•  Approval of the audited Annual Report for 2023•  Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.•  Approval of the Remuneration Report fo...

 PRESS RELEASE

Invitation to the annual shareholders’ meeting

Invitation to the annual shareholders’ meeting The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a ...

 PRESS RELEASE

Share-based legacy RSU program granted

Share-based legacy RSU program granted Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch